Chimeric derivatives of hepatitis B virus core particles carrying major epitopes of the rubella virus E1 glycoprotein

Clinical and Vaccine Immunology

Volumn 20, Issue 11, 2013, Pages 1719-1728

  Skrastina, Dace ^a   Petrovskis, Ivars ^a   Petraityte, Rasa ^b   Sominskaya, Irina ^b   Ose, Velta ^a   Liekniņa, Ilva ^a   Bogans, Janis ^a   Sasnauskas, Kestutis ^b   Pumpens, Paul ^a  

^a LATVIAN BIOMEDICAL RESEARCH AND STUDY CENTRE   (Latvia)

^b VILNIUS UNIVERSITY   (Lithuania)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HEPATITIS B VIRUS CARBOXY TERMINAL TRUNCATED CORE E1 GLYCOPROTEIN [214-240]; HEPATITIS B VIRUS CARBOXY TERMINAL TRUNCATED CORE E1 GLYCOPROTEIN [214-285]; HEPATITIS B VIRUS CARBOXY TERMINAL TRUNCATED CORE E1 GLYCOPROTEIN [245-285]; RECOMBINANT VACCINE; RUBELLA VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIBODY TITER; ANTIGEN RECOGNITION; ANTIGENICITY; ARTICLE; BACTERIAL CELL; CELL LYSATE; CONTROLLED STUDY; FEMALE; HUMORAL IMMUNITY; LIGHT SCATTERING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PURIFICATION; PROTEIN REFOLDING; PROTEIN STRUCTURE; RUBELLA VIRUS; VIRUS LIKE AGENT;

ANIMALS; ANTIBODIES, VIRAL; EPITOPES; ESCHERICHIA COLI; FEMALE; HEPATITIS B VIRUS; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; MICROSCOPY, ELECTRON, TRANSMISSION; RUBELLA VACCINE; VACCINES, SYNTHETIC; VACCINES, VIRUS-LIKE PARTICLE; VIRAL ENVELOPE PROTEINS;

EID: 84886732776     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00533-13     Document Type: Article

References (42)

1. Bart SW, Stelter HC, Preblud SR, Williams NM, Orenstein WA, Bart KJ, Hinman AR, Herrmann KL. 1985. Fetal risk associated with rubella vaccine: an update. Rev. Infect. Dis. 7(Suppl 1):S95-S102.
2. Plotkin SA, Cornfeld D, Ingalls TH. 1965. Studies of immunization with living rubella virus. Trials in children with a strain cultured from an aborted fetus. Am. J. Dis. Child. 110:381-389.
3. Plotkin SA, Farquhar J, Katz M, Ingalls TH. 1967. A new attenuated rubella virus grown in human fibroblasts: evidence for reduced nasopharyngeal excretion. Am. J. Epidemiol. 86:468-477.
4. Wharton M, Cochi SL, Williams WW. 1990. Measles, mumps, and rubella vaccines. Infect. Dis. Clin. North. Am. 4:47-73.
5. Oker-Blom C, Kalkkinen N, Kääriäinen L, Pettersson RF. 1983. Rubella virus contains one capsid protein and three envelope glycoproteins, E1, E2a, and E2b. J. Virol. 46:964-973.
6. Green KY, Dorsett PH. 1986. Rubella virus antigens: localization of epitopes involved in hemagglutination and neutralization by using monoclonal antibodies. J. Virol. 57:893-898.
7. Wolinsky JS, Sukholutsky E, Moore WT, Lovett A, McCarthy M, Adame B. 1993. An antibody- and synthetic peptide-defined rubella virus E1 glycoprotein neutralization domain. J. Virol. 67:961-968.
8. Cordoba P, Grutadauria S, Cuffini C, Zapata M. 2000. Neutralizing monoclonal antibody to the E1 glycoprotein epitope of rubella virus mediates virus arrest in VERO cells. Viral Immunol. 13:83-92.
9. Mitchell LA, Decarie D, Tingle AJ, Zrein M, Lacroix M. 1993. Characterization of rubella virus-specific antibody responses by using synthetic peptides. Virus Res. 29:33-57.
10. Chaye H, Chong P, Tripet B, Brush B, Gillam S. 1992. Localization of the virus neutralizing and hemagglutinin epitopes of E1 glycoprotein of rubella virus. Virology 189:483-492.
11. Terry GM, Ho-Terry L, Londesborough P, Rees KR. 1988. Localization of the rubella E1 epitopes. Arch. Virol. 98:189-197.
12. Perrenoud G, Messerli F, Thierry AC, Beltraminelli N, Cousin P, Fasel N, Vallet V, Demotz S, Duchosal MA, Moulon C. 2004. A recombinant rubella E1 glycoprotein as a rubella vaccine candidate. Vaccine 23:480-488.
13. Newton SE, Clarke BE, Appleyard G, Francis MJ, Carroll AR, Rowlands DJ, Skehel J, Brown F. 1987. New approaches to FMDV antigen presentation using vaccinia virus, p 12-21. In Chanock RM, Lerner RA, Brown F, Ginsberg H (ed), Vaccines 87. Modern approaches to new vaccines: prevention of AIDS and other viral, bacterial and parasitic diseases. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
14. Clarke BE, Newton SE, Carroll AR, Francis MJ, Appleyard G, Syred AD, Highfield PE, Rowlands DJ, Brown F. 1987. Improved immunogenicity of a peptide epitope after fusion to hepatitis B core protein. Nature 330:381-384.
15. Borisova G, Bundule M, Grinstein E, Dreilina D, Dreimane A, Kalis J, Kozlovskaya T, Loseva V, Ose V, Pumpen P, Pushko P, Snikere D, Stankevica E, Tsibinogin V, Gren EJ. 1987. Recombinant capsid structures for exposure of protein antigenic epitopes. Mol. Gen. (Life Sci. Adv.) 6:169-174.
16. Pumpens P, Grens E. 2001. HBV core particles as a carrier for B cell/T cell epitopes. Intervirology 44:98-114.
17. Pumpens P, Grens E. 2002. Artificial genes for chimeric virus-like particles, p 249-327. In Khudyakov YE, Fields HA (ed), Artificial DNA: methods and applications. CRC Press LLC, Boca Raton, FL.
18. Pumpens P, Ulrich R, Sasnauskas K, Kazaks A, Ose V, Grens E. 2008. Construction of novel vaccines on the basis of the virus-like particles: hepatitis B virus proteins as vaccine carriers, p 205-248. In Khudyakov Y (ed), Medicinal protein engineering. CRC Press, Taylor & Francis Group, Boca Raton, FL.
19. Roose K, De Baets S, Schepens B, Saelens X. 2013. Hepatitis B core-based virus-like particles to present heterologous epitopes. Expert Rev. Vaccines 12:183-198.
20. Zhou S, Standring DN. 1992. Hepatitis B virus capsid particles are assembled from core-protein dimer precursors. Proc. Natl. Acad. Sci. U. S. A. 89:10046-10050.
21. Wingfield PT, Stahl SJ, Williams RW, Steven AC. 1995. Hepatitis core antigen produced in Escherichia coli: subunit composition, conformational analysis, and in vitro capsid assembly. Biochemistry 34:4919-4932.
22. Packianathan C, Katen SP, CEDann 3rd, Zlotnick A. 2010. Conformational changes in the hepatitis B virus core protein are consistent with a role for allostery in virus assembly. J. Virol. 84:1607-1615.
23. Crowther RA, Kiselev NA, Böttcher B, Berriman JA, Borisova GP, Ose V, Pumpens P. 1994. Three dimensional structure of hepatitis B virus core particles determined by electron cryo-microscopy. Cell 77:943-950.
24. Roseman AM, Borschukova O, Berriman JA, Wynne SA, Pumpens P, Crowther RA. 2012. Structures of hepatitis B virus cores presenting a model epitope and their complexes with antibodies. J. Mol. Biol. 423:63-78.
25. Wynne SA, Crowther RA, Leslie AG. 1999. The crystal structure of the human hepatitis B virus capsid. Mol. Cell 3:771-780.
26. Mihailova M, Boos M, Petrovskis I, Ose V, Skrastina D, Fiedler M, Sominskaya I, Ross S, Pumpens P, Roggendorf M, Viazov S. 2006. Recombinant virus-like particles as a carrier of B- and T-cell epitopes of hepatitis C virus (HCV). Vaccine 24:4369-4377.
27. Bichko V, Schodel F, Nassal M, Gren E, Berzinsh I, Borisova G, Miska S, Peterson DL, Gren E, Pushko P, Will H. 1993. Epitopes recognized by antibodies to denatured core protein of hepatitis B virus. Mol. Immunol. 30:221-231.
28. Sasnauskas K, Buzaite O, Vogel F, Jandrig B, Razanskas R, Staniulis J, Scherneck S, Krüger DH, Ulrich R. 1999. Yeast cells allow high-level expression and formation of polyomavirus-like particles. Biol. Chem. 380:381-386.
29. Razanskiene A, Schmidt J, Geldmacher A, Ritzi A, Niedrig M, Lundkvist A, Krüger DH, Meisel H, Sasnauskas K, Ulrich R. 2004. High yields of stable and highly pure nucleocapsid proteins of different hantaviruses can be generated in the yeast Saccharomyces cerevisiae. J. Biotechnol. 111:319-333.
30. Sasnauskas K, Bulavaite A, Hale A, Jin L, Knowles WA, Gedvilaite A, Dargevicīte A, Bartkevicīte D, Zvirbliene A, Staniulis J, Brown DW, Ulrich R. 2002. Generation of recombinant virus-like particles of human and non-human polyomaviruses in yeast Saccharomyces cerevisiae. Intervirology 45:308-317.
31. Slibinskas R, Samuel D, Gedvilaite A, Staniulis J, Sasnauskas K. 2004. Synthesis of the measles virus nucleoprotein in yeast Pichia pastoris and Saccharomyces cerevisiae. J. Biotechnol. 107:115-124.
32. Gros C, Linder M, Wengler G, Wengler G. 1997. Analyses of disulfides present in the rubella virus E1 glycoprotein. Virology 230:179-186.
33. Frey TK. 1994. Molecular biology of rubella virus. Adv. Virus Res. 44:69-160.
34. Liu XL, Wu B, Zhang WQ, Song YY, Xu HZ, Wang GT, Wang ZY. 2009. Effects of disulfide bridges glycoprotein E1 on fusogenic activity of Rubella virus. Acta Virol. 53:29-34.
35. Spohn G, Jennings GT, Martina BE, Keller I, Beck M, Pumpens P, Osterhaus AD, Bachmann MF. 2010. A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice. Virol. J. 7:146.
36. Bachmann MF, Dyer MR. 2004. Therapeutic vaccination for chronic diseases: a new class of drugs in sight. Nat. Rev. Drug Discov. 3:81-88.
37. Zeltins A. 2013. Construction and characterization of virus-like particles: a review. Mol. Biotechnol. 53:92-107.
38. Pushko P, Pumpens P, Grens E. 2013. Development of virus-like particle technology from small highly symmetric to large complex virus-like particle structures. Intervirology 56:141-165.
39. Rosenberg AS. 2006. Effects of protein aggregates: an immunologic perspective. AAPS J. 8:E501-E507.
40. Kelly EP, Greene JJ, King AD, Innis BL. 2000. Purified dengue 2 virus envelope glycoprotein aggregates produced by baculovirus are immunogenic in mice. Vaccine 18:2549-2559.
41. Gupta RK, Siber GR. 1995. Adjuvants for human vaccines - current status, problems and future prospects. Vaccine 13:1263-1276.
42. Bichko V, Pushko P, Dreilina D, Pumpen P, Gren E. 1985. Subtype ayw variant of hepatitis B virus. DNA primary structure analysis. FEBS Lett. 185:208-212.